LHON Society perspective on the European Commission authorisation of Raxone
GenSight LHON Gene Therapy Clinical Trials
GenSight Biologics has launched two pivotal Phase 3 clinical trials of its gene therapy product GS010 for patients with Leber hereditary optic neuropathy (LHON) carrying the 11778 mitochondrial DNA mutation. Moorfields Eye Hospital in London is now actively recruiting for the UK with Mr Patrick Yu Wai Man (Consultant Ophthalmologist) as the lead investigator.
The main inclusion criteria:
(1) Confirmed LHON with the 11778 mitochondrial DNA mutation
(2) Disease duration of less than 12 months (in both eyes)
(3) Age 18 years or older
Travel expenses and accommodation in London will be fully covered.
Further details can be found in this press release on the GenSight website
Information on the clinical trials can also be found here on the Clinicaltrials.gov website
25th June 2015 EMA Statement on Raxone (Idebenone)
Bascom Palmer Eye Institute LHON gene therapy clinical trial (initial results)